Providers and Patients Can Help Minimize Risks of Steroid-Induced Osteoporosis, ACR Says
On September 14, 2022, the American College of Rheumatology (ACR) released a summary of updated guidelines (PDF) on how to manage glucocorticoid-induced osteoporosis (GIOP), a condition that can occur in people who take steroids as part of their treatment. The full manuscript is expected to be released in 2023.The update comes five years after ACR’s 2017 recommendations and incorporates information on more recent osteoporosis treatments, namely Tymlos (abaloparatide) and Evenity (romosozumab), as well as recommendations for sequential therapy to prevent rebound fractures.Steroids Relieve Symptoms, Treat Many Conditions, but Can Increase Osteoporosis RiskGlucocorticoids (GCs) can relieve the inflammation and pain common in rheumatic diseases such as rheumatoid arthritis (RA) as well as other chronic conditions, including multiple sclerosis (MS), Crohn’s disease, ulcerative colitis (UC), psoriasis, atopic dermatitis, allergies and asthma, and heart failure.RELATED:…